Granahan Investment Management Inc. MA bought a new stake in Esperion Therapeutics Inc (NASDAQ:ESPR) during the 2nd quarter, HoldingsChannel.com reports. The firm bought 107,350 shares of the biopharmaceutical company’s stock, valued at approximately $4,207,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $2,247,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at about $250,000. Neuberger Berman Group LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at about $1,302,000. Partner Fund Management L.P. grew its position in shares of Esperion Therapeutics by 117.7% in the second quarter. Partner Fund Management L.P. now owns 2,460,157 shares of the biopharmaceutical company’s stock valued at $96,414,000 after purchasing an additional 1,330,159 shares during the period. Finally, Swiss National Bank grew its position in shares of Esperion Therapeutics by 15.6% in the second quarter. Swiss National Bank now owns 41,500 shares of the biopharmaceutical company’s stock valued at $1,626,000 after purchasing an additional 5,600 shares during the period.

Several brokerages have recently issued reports on ESPR. Stifel Nicolaus began coverage on shares of Esperion Therapeutics in a research report on Friday. They issued a “buy” rating and a $89.00 target price on the stock. ValuEngine upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. BidaskClub upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 21st. Zacks Investment Research lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Finally, Northland Securities lowered shares of Esperion Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Two analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $80.58.

In related news, Director Roger S. Newton sold 17,700 shares of the business’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $51.05, for a total transaction of $903,585.00. Following the transaction, the director now directly owns 615,726 shares in the company, valued at $31,432,812.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Target N. V. Biotech purchased 50,000 shares of the stock in a transaction that occurred on Friday, June 29th. The shares were acquired at an average price of $39.48 per share, for a total transaction of $1,974,000.00. Following the completion of the transaction, the insider now directly owns 3,182,964 shares of the company’s stock, valued at approximately $125,663,418.72. The disclosure for this purchase can be found here. Insiders have purchased 210,000 shares of company stock worth $8,683,700 over the last 90 days. 14.50% of the stock is currently owned by company insiders.

ESPR opened at $47.19 on Tuesday. The stock has a market cap of $1.29 billion, a P/E ratio of -6.76 and a beta of 2.25. Esperion Therapeutics Inc has a twelve month low of $33.06 and a twelve month high of $82.68.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.01). During the same period in the previous year, the business posted ($1.92) EPS. analysts anticipate that Esperion Therapeutics Inc will post -6.28 EPS for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: Index Funds

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.